rectogesic 4 mg/g rektaalivoide
kyowa kirin holdings b.v. - glycerol trinitrate - rektaalivoide - 4 mg/g - glyseryylitrinitraatti
dehydrobenzperidol 2.5 mg/ml injektioneste, liuos
kyowa kirin holdings b.v. - droperidol - injektioneste, liuos - 2.5 mg/ml - droperidoli
tostran 2 % geeli
kyowa kirin holdings b.v. - testosterone - geeli - 2 % - testosteroni
abstral 100 mikrog resoribletti
kyowa kirin holdings b.v. - fentanyl citrate - resoribletti - 100 mikrog - fentanyyli
abstral 200 mikrog resoribletti
kyowa kirin holdings b.v. - fentanyl citrate - resoribletti - 200 mikrog - fentanyyli
abstral 300 mikrog resoribletti
kyowa kirin holdings b.v. - fentanyl citrate - resoribletti - 300 mikrog - fentanyyli
abstral 400 mikrog resoribletti
kyowa kirin holdings b.v. - fentanyl citrate - resoribletti - 400 mikrog - fentanyyli
abstral 600 mikrog resoribletti
kyowa kirin holdings b.v. - fentanyl citrate - resoribletti - 600 mikrog - fentanyyli
abstral 800 mikrog resoribletti
kyowa kirin holdings b.v. - fentanyl citrate - resoribletti - 800 mikrog - fentanyyli
crysvita
kyowa kirin holdings b.v. - burosumab - hypophosphatemia, familial; hypophosphatemic rickets, x-linked dominant; osteomalacia - lääkkeet luusairauksien hoitoon - crysvita is indicated for the treatment of x-linked hypophosphataemia, in children and adolescents aged 1 to 17 years with radiographic evidence of bone disease, and in adults. crysvita is indicated for the treatment of fgf23-related hypophosphataemia in tumour-induced osteomalacia associated with phosphaturic mesenchymal tumours that cannot be curatively resected or localised in children and adolescents aged 1 to 17 years and in adults.